PDCD1 and non-small cell lung carcinoma: Toripalimab, a humanized IgG4 anti-programmed cell death-1 (PD-1) monoclonal antibody, combined with chemotherapy as neoadjuvant therapy before radical surgery in stage II/III NSCLC significantly improved event-free survival (EFS) than neoadjuvant chemotherapy (P<0.001), in the randomized, phase III NEOTORCH trial (14).